Van den Bosch Filip, De Keyser Filip, Mielants Herman, Veys Eric M
University Hospital, Department of Rheumatology, Gent, Belgium.
Arthritis Res Ther. 2005;7(3):121-3. doi: 10.1186/ar1742. Epub 2005 Apr 11.
Blocking tumor necrosis factor-alpha either with monoclonal antibodies or with soluble receptor constructs has been proven to be effective with an acceptable safety profile in patients with rheumatoid arthritis, and more recently also in the diseases belonging to the spondyloarthropathy concept. Nevertheless multiple questions still remain unresolved especially concerning longer-term treatment. Data from a recent manuscript by Baraliakos and colleagues seem to indicate that at least for the vast majority of ankylosing spondylitis patients treatment with infliximab can not be withdrawn, if one wants to control disease activity in a continuous way. Although still unproven, this might be of crucial importance with regard to structure modification and prevention of ankylosis in this chronic inflammatory disorder.
已证实，使用单克隆抗体或可溶性受体构建体阻断肿瘤坏死因子-α，对于类风湿性关节炎患者具有可接受的安全性，且效果显著。最近，在属于脊柱关节病范畴的疾病中也得到了验证。然而，仍有诸多问题尚未解决，尤其是关于长期治疗的问题。Baraliakos及其同事近期发表的一篇论文中的数据似乎表明，至少对于绝大多数强直性脊柱炎患者而言，如果想要持续控制疾病活动，就不能停用英夫利昔单抗治疗。尽管尚未得到证实，但这对于这种慢性炎症性疾病的结构改变和强直预防可能至关重要。
